{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T17:52:53Z","timestamp":1726163573714},"reference-count":12,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory\nSyndrome Coronavirus 2 (SARS-CoV-2\/2019-nCoV). Though many classes of drugs have\nbeen advocated\/used for the treatment of this disease, vaccines are being targeted for its ultimate\nprevention. Indian Government has approved Covishield (ChAdOx1 nCoV19 Corona Virus\nVaccine-Recombinant) for restricted use in emergency circumstances.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study is aimed at evaluating the safety profile of the Covishield vaccine among\nhealthcare workers in a tertiary care hospital.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>All Adverse Drug Reactions (ADRs) reported to the ADR monitoring centre by healthcare\nworkers who received the Covishield vaccine during the study period of 3 months were analysed\non various parameters, and the assessment was done using the WHO-UMC scale.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>During the study period, a total of 1216 beneficiaries were vaccinated with 1st dose of Covishield,\nand out of these, 727 beneficiaries also received 2nd dose of the vaccine. Out of the 1216\nbeneficiaries vaccinated, 69 ADRs were reported in 24 healthcare workers. The most common\nADR reported was fever (24.64%), followed by myalgia (18.84%). No death or any serious anaphylactic\nreaction was observed. None of the healthcare workers experienced any adverse event during\nthe observation period of 30 minutes. Serious reactions were reported in 4 healthcare workers as\nper the Pharmacovigilance Programme of India (PvPI) criteria of serious AEFI. 92% of healthcare\nworkers recovered from ADRs during the study period. 84% of ADRs were classified as probable\nas per the WHO-UMC scale.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>As per the Government of India directives, all the healthcare workers in the institute\nwere encouraged to take both doses of the Covishield vaccine. The beneficiaries were kept under\nobservation for 30 minutes and monitored for any adverse drug reaction following vaccination. The\nvaccine was found to be safe with a very low incidence of ADRs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886317666220113101815","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T13:13:12Z","timestamp":1642684392000},"page":"344-349","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["ADR Profile of the Covishield Vaccine Among Healthcare Workers in a\nTertiary Care Teaching Hospital in India"],"prefix":"10.2174","volume":"17","author":[{"given":"Tirthankar","family":"Deb","sequence":"first","affiliation":[{"name":"Adverse Drug Reaction Monitoring Centre, Department of Pharmacology, Kalpana Chawla Govt. Medical College,\nKarnal, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Kalpana Chawla Govt. Medical College, Karnal,\nHaryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manmeet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Adverse Drug Reaction Monitoring Centre, Department of Pharmacology, Kalpana Chawla Govt. Medical College,\nKarnal, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankita","family":"Beniwal","sequence":"additional","affiliation":[{"name":"Adverse Drug Reaction Monitoring Centre, Department of Pharmacology, Kalpana Chawla Govt. Medical College,\nKarnal, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varsha","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Kalpana Chawla Govt. Medical College, Karnal,\nHaryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jiph.2020.03.019","volume":"13","author":"Harapan H.","year":"2020","unstructured":"Harapan H.; Itoh N.; Yufika A.; Winardi W.; Keam S.; Te H.; Megawati D.; Hayati Z.; Wagner A.L.; Mudatsir M.; Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health 2020,13(5),667-673","journal-title":"J Infect Public Health"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"105951","DOI":"10.1016\/j.ijantimicag.2020.105951","volume":"55","author":"Li H.","year":"2020","unstructured":"Li H.; Liu S.M.; Yu X.H.; Tang S.L.; Tang C.K.; Coronavirus disease 2019 (COVID-19): Current status and future perspectives. Int J Antimicrob Agents 2020,55(5),105951","journal-title":"Int J Antimicrob Agents"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"Wiersinga W.J.","year":"2020","unstructured":"Wiersinga W.J.; Rhodes A.; Cheng A.C.; Peacock S.J.; Prescott H.C.; Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 2020,324(8),782-793","journal-title":"JAMA"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12098-020-03263-6","volume":"87","author":"Singhal T.","year":"2020","unstructured":"Singhal T.; A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020,87(4),281-286","journal-title":"Indian J Pediatr"},{"key":"ref=5","first-page":"1","volume":"15","author":"Goel A.","year":"2020","unstructured":"Goel A.; Mittal R.; Beniwal. A coronavirus: Genetic organization, infestation, pathophysiological impacts, diagnostics and therapeutics in COVID-19. JOHP 2020,15(4),1","journal-title":"JOHP"},{"key":"ref=6","year":"2021","unstructured":"India: Fact sheet covishield 2021 Serum institute of India Available from:  2021"},{"key":"ref=7","first-page":"388","volume":"52","author":"Ophinni Y.","year":"2020","unstructured":"Ophinni Y.; Hasibuan A.S.; Widhani A.; Maria S.; Koesnoe S.; Yunihastuti E.; Karjadi T.H.; Rengganis I.; Djauzi S.; COVID-19 vaccines: Current status and implication for use in Indonesia. Acta Med Indones 2020,52(4),388-412","journal-title":"Acta Med Indones"},{"key":"ref=8","year":"2021","unstructured":"COVID-19 vaccination drive to begin from January 16 in India. India: Hindustan Times 2021  Available from:  2021","journal-title":"India: Hindustan Times 2021"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"Folegatti PM","year":"2020","unstructured":"Folegatti PM; Ewer KJ; Aley PK; Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 2020,396(10249),467-78","journal-title":"Lancet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"Zhu FC","year":"2020","unstructured":"Zhu FC; Li YH; Guan XH; Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020,395(10240),1845-54","journal-title":"Lancet"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.3346\/jkms.2021.36.e107","volume":"36","author":"Kim S","year":"2021","unstructured":"Kim S; Wi YM; Yun SY; Ryu JS; Shin JM; Lee EH; Adverse events in healthcare workers after the first dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 vaccination: A single center experience. J Korean Med Sci 2021,36(14),e107","journal-title":"J Korean Med Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"Voysey M.","year":"2021","unstructured":"Voysey M.; Ann S.; Clemens C.; Madhi S.A.; Weckx L.Y.; Folegatti P.M.; Articles safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021,397(10269),99-111","journal-title":"Lancet"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220113101815","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200199\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220113101815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T09:54:49Z","timestamp":1667469289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200199\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886317666220113101815","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}